

**NOTICE FROM THE EXECUTIVE OFFICER
July 31, 2008**

No Change to the Drug Benefit Price for ZANTAC®

I am aware that a bulletin was issued on July 30, 2008 by GlaxoSmithKline Inc. which communicated proposed price changes to Zantac® tablets in 150 mg 60's and Zantac® 300 mg 30's. I am writing to clarify that there will be no price adjustments made to the Ontario Drug Benefit (ODB) Formulary for the above-named products until further notice.

Please note that the ministry will proceed to issue a Call for Applications for the ranitidine molecule, which includes Zantac, on Friday, August 1, 2008.

Helen Stevenson
Executive Officer, Ontario Public Drug Programs